Sichuan Hexie Shuangma's (SHE:000935) subsidiary, Hubei Jianxiang Biopharmaceutical, passed the US Food and Drug Administration's current good manufacturing practice on-site inspection, according to a Shenzhen bourse filing on Friday.
The inspection, a drug quality assurance inspection, was conducted between March 10 and March 14 in a production line for active pharmaceutical ingredients, such as tirzepatide, semaglutide, liraglutide, and oxytocin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments